# Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

> **NCT01915602** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 14 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Refametinib (BAY86-9766)
- **DRUG:** Sorafenib (BAY43-9006)

## Key facts

- **NCT ID:** NCT01915602
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-27
- **Primary completion:** 2015-07-29
- **Final completion:** 2017-02-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01915602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01915602, "Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01915602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*